Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have received cyclosporine-based immunosuppressive therapy for more than 6 months， and have maintained a stable regimen for at least 8 weeks before enrollment~* The trough blood level of cyclosporine maintained at 50-200ng/ml at least 4 weeks before enrollment~* SCr\< 200 μmol/l ( 2.3 mg/dl)~* Females of childbearing potential must have a negative pregnancy test within 48 hrs prior to randomization and reliable methods of contraception should be started 4 weeks prior to and during the whole study~* Understand and sign the approved informed consent form~Exclusion Criteria:~* Patients who have had other solid organ transplantations~* 24 hours proteinuria\>2g~* SGPT/ALT，SGOT/AST or total bilirubin rising to more than double the normal level~* Patients suffering from serious infection lesions~* Patients have severe diarrhea or vomiting, peptic ulcer and/or defective absorption~* Patients have severe heart, lung disease, abnormal glucose tolerance or malignant tumor history~* Known contraindication to administration of Tacrolimus. Subject has known hypersensitivity to tacrolimus, or any of the product excipients~* Pregnancy or lactating women~* Patients have participated in another clinical trial in the past month~* Patient refuses to sign informed consent form~* Patient not willing to continue in the study and wants to withdraw from the study~* Poor adherence or lost to follow-up~* Violation of protocol~* Severe adverse events occurred need to withdraw the study according to investigator's judgment~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ADV group (Type: EXPERIMENTAL): Once daily
- PRG group (Type: EXPERIMENTAL): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).